Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen [Phase 3]
Phase 3 trial evaluating atezolizumab in combination with enzalutamide for metastatic castration-resistant prostate cancer after AR pathway …
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. [Phase 2]
A Phase II study evaluating enzalutamide and ARv7 in metastatic castration-resistant prostate cancer with visceral metastases has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer [Phase 3]
Phase 3 trial of tasquinimod in Asian chemo-naïve patients with metastatic castration-resistant prostate cancer was terminated; results post…
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients [Phase 1, Phase 2]
Phase 1/2A study of TRC253, an androgen receptor antagonist, in metastatic castration-resistant prostate cancer completed with results poste…
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the effects of Coenzyme A combined with Abiraterone in patients with castration-resistant prostate cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer [Phase 3]
Phase III study evaluating DCVAC/PCa added to standard chemotherapy for metastatic castration-resistant prostate cancer has completed with r…
-
FDA approval · 2021-04-05FDA Approved: ABIRATERONE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for ABIRATERONE ACETATE (BluePoint Laboratories) under ANDA 210686.
-
FDA approval · 2021-04-05FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Florida Pharmaceutical Products, LLC.)
FDA approved a supplemental application for Abiraterone acetate from Florida Pharmaceutical Products, LLC., representing a supplemental appr…
-
FDA approval · 2021-04-05FDA Approved: ABIRATERONE ACETATE — Supplemental Application (NORTHSTAR RX LLC)
FDA approved a supplemental application for abiraterone acetate (generic version). The product is manufactured by NorthStar RX LLC.
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy [Phase 2]
Phase 2 trial of Lu-177 PSMA-directed endoradiotherapy for metastatic castration-resistant prostate cancer was terminated; results posted in…
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: Oral Calcitriol With Ketoconazole in CRPC [Phase 2]
Phase 2 clinical trial evaluating oral calcitriol with ketoconazole in castration-resistant prostate cancer; study terminated with results p…
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy [Phase 2]
This Phase 2 clinical trial update investigates genetic and molecular factors associated with response to enzalutamide in prostate cancer, i…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer [NA]
Clinical trial update on a home-based exercise intervention for patients with metastatic castration-resistant prostate cancer undergoing and…
-
CLINICAL_TRIALS trial_result · 2020-12-23Clinical Trial Update: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of enzalutamide and cabazitaxel for metastatic castration-resistant prostate cancer; results were…
-
FDA approval · 2020-12-18FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Jevtana (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2020-12-14FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Abiraterone Acetate from Mylan Pharmaceuticals Inc., supporting the availability of a generi…
-
CLINICAL_TRIALS trial_result · 2020-12-09Clinical Trial Update: A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide [Phase 4]
Phase 4 trial evaluating whether Enzalutamide increases seizure risk in metastatic castration-resistant prostate cancer; results have been p…
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating GS-5829 (alobresib) as a single agent and with enzalutamide in metastatic castration-resistant prostate cancer; s…
-
FDA approval · 2020-11-20FDA Approved: ABIRATERONE ACETATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's supplemental application for Abiraterone acetate, a generic version of the cancer drug.
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. [Phase 2]
Phase 2 trial update evaluating abiraterone acetate with docetaxel after progression to abiraterone in metastatic castration-resistant prost…
-
CLINICAL_TRIALS trial_result · 2020-11-12Clinical Trial Update: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial evaluating abiraterone acetate and prednisone with or without veliparib in metastatic castration-resistant prostate cancer has…
-
FDA approval · 2020-10-23FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) from Astellas Pharma US to modify/expand its label for prostate cancer ind…
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 dose-finding study of GSK2636771 in combination with enzalutamide in metastatic castration-resistant prostate cancer completed.
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating selegiline in combination with docetaxel for metastatic castration-resistant prostate cancer; current stat…
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) [Phase 3]
Phase 3 trial comparing Olaparib to enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer has completed wi…